McDermott advises Ampersand on investment in BioEcho Life Sciences

Overview


Frankfurt a.M., March 23, 2021 – McDermott Will & Emery advised Ampersand Capital Partners on the acquisition of a minority stake in BioEcho Life Sciences GmbH.

BioEcho Life Sciences GmbH, founded in 2016 in Cologne, Germany, develops and markets nucleic acid purification solutions for molecular diagnostics and life science research. The company’s CE-marked viral RNA extraction kit recently played a critical role in simplifying the evaluation of SARS-CoV-2 testing in Europe.

Founded in 1988, U.S. private equity investor Ampersand Capital Partners specializes in growth investments in the healthcare and life sciences sectors. With offices in Boston and Amsterdam, Ampersand currently manages more than $2 billion in assets.

McDermott regularly advises Ampersand. Led by Frankfurt partner Michael Cziesla, the transaction once again documents McDermott`s special expertise in the healthcare sector. BioEcho Life Sciences GmbH and its shareholders were advised by Hamburg-based corporate boutique Pier11.

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts